[1]钟彦波,姚 艳,李沼萍,等.恩格列净联合阿托伐他汀钙片在老年糖尿病患者中的应用及对血脂水平的影响研究[J].医学信息,2025,38(24):127-131.[doi:10.3969/j.issn.1006-1959.2025.24.026]
　ZHONG Yanbo,YAO Yan,LI Zhaoping,et al.Study on the Application of Empagliflozin Combined with Atorvastatin Calcium Tabletsin Elderly Diabetes Mellitus Patients and its Effect on Blood Lipid Levels[J].Journal of Medical Information,2025,38(24):127-131.[doi:10.3969/j.issn.1006-1959.2025.24.026]
点击复制

恩格列净联合阿托伐他汀钙片在老年糖尿病患者中的应用及对血脂水平的影响研究()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年24期
页码:
127-131
栏目:
论著
出版日期:
2025-12-15

文章信息/Info

Title:
Study on the Application of Empagliflozin Combined with Atorvastatin Calcium Tabletsin Elderly Diabetes Mellitus Patients and its Effect on Blood Lipid Levels
文章编号:
1006-1959（2025）24-0127-05
作者:
钟彦波1; 姚 艳2; 李沼萍3; 陈 慧4
安福县人民医院内二科1，血液透析室2，药剂科3，运行办4，江西 安福 343200
Author(s):
ZHONG Yanbo1;  YAO Yan2;  LI Zhaoping3;  CHEN Hui4
The Second Department of Internal Medicine1, Hemodialysis Room2, Department of Pharmacy3, Operation Office4,Anfu County People′s Hospital, AnFu 343200, Jiangxi, China
关键词:
糖尿病; 恩格列净; 阿托伐他汀钙片; 血脂水平; 炎症因子
Keywords:
Diabetes mellitus;  Empagliflozin;  Atorvastatin calcium tablets;  Blood lipid levels;  Inflammatory factors
分类号:
R587.1
DOI:
10.3969/j.issn.1006-1959.2025.24.026
文献标志码:
A
摘要:
目的 探究恩格列净（EMPA）联合阿托伐他汀钙片（ATO）在老年糖尿病患者中的应用效果及对血脂水平的影响。方法 以2024年1月-2025年2月安福县人民医院收治的62例老年糖尿病患者为研究对象，经随机数字表法分为对照组（31例）和观察组（31例），对照组采用EMPA治疗，观察组应用EMPA+ATO治疗，比较两组血糖水平[空腹血糖（FPG）、餐后2小时血糖（2h PPG）、糖化血红蛋白（HbA1c）]、血脂水平[高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）、总胆固醇（TC）、甘油三酯（TG）]、炎症因子[白细胞介素-6（IL-6）、白细胞介素-10（IL-10）、肿瘤坏死因子α（TNF-α）、超敏C反应蛋白（hs-CRP）]、心血管系统指标[E峰、左室射血分数（LVEF）、左心室质量指数]、血清尿酸（SUA）、血清钠离子（Na+）、生活质量（SF-36评分）、不良反应。结果 两组治疗后血糖水平（FPG、2h PPG、HbA1c）均较治疗前下降（P＜0.05），但组间比较，差异无统计学意义（P＞0.05）。与对照组比较，观察组治疗后HDL-C更高、LDL-C、TC、TG更低（P＜0.05）。两组治疗后炎症因子（IL-6、IL-10、TNF-α、hs-CRP）均较治疗前下降，且与对照组比较，观察组IL-6、IL-10、TNF-α、hs-CRP更低（P＜0.05）。两组治疗后心血管系统指标（E峰、LVEF、左心室质量指数）均较治疗前改善，且与对照组比较，观察组E峰、LVEF更高，左心室质量指数更低（P＜0.05）。两组治疗后血清尿酸较治疗前下降，Na+、SF-36分数较治疗前升高，且与对照组比较，观察组血清尿酸更低，Na+、SF-36分数更高（P＜0.05）。两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 EMPA联合ATO可有效改善老年糖尿病患者的血糖、血脂及心血管系统指标，下调其炎症因子与尿酸水平，提升患者血清Na+水平与生活质量，具有良好用药安全性。
Abstract:
Objective To explore the application effect of empagliflozin (EMPA) combined with atorvastatin calcium tablets (ATO) in elderly diabetic patients and its effect on blood lipid levels. Methods A total of 62 elderly patients with diabetes mellitus admitted to Anfu County People′s Hospital from January 2024 to February 2025 were randomly divided into control group (31 patients) and observation group (31 patients). The control group was treated with EMPA, and the observation group was treated with EMPA+ATO. The blood glucose levels [fasting plasma glucose (FPG), 2-hour postprandial plasma glucose (2h PPG), glycated hemoglobin (HbA1c)], blood lipid levels [high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglyceride (TG)], inflammatory factors [interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor-α (TNF-α), high-sensitivity C-reactive protein (hs-CRP)], cardiovascular system indexes [E peak, left ventricular ejection fraction (LVEF), left ventricular mass index], serum uric acid (SUA), serum sodium ion (Na+), quality of life (SF-36 score), and adverse reactions were compared between the two groups. Results The blood glucose levels (FPG, 2h PPG, HbA1c) of the two groups after treatment were lower than those before treatment (P<0.05), with no statistically significant difference between the groups (P>0.05). compared with the control group, the observation group had higher HDL-C and lower LDL-C, TC, TG after treatment (P<0.05). After treatment, the inflammatory factors (IL-6, IL-10, TNF-α, hs-CRP) in the two groups were lower than those before treatment, and compared with the control group, the observation group had lower IL-6, IL-10, TNF-α, hs-CRP (P<0.05). After treatment, the cardiovascular system indexes (E peak, LVEF, left ventricular mass index) of the two groups were better than those before treatment, and compared with the control group, the E peak and LVEF of the observation group were higher, and the left ventricular mass index was lower (P<0.05). After treatment, the serum uric acid in the two groups was lower than that before treatment, and Na+ and SF-36 score were higher than those before treatment, compared with the control group, the serum uric acid in the observation group was lower, and Na+ and SF-36 score were higher (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion EMPA combined with ATO can effectively improve the blood glucose, blood lipid and cardiovascular system indexes of elderly diabetic patients, down-regulate the levels of inflammatory factors and uric acid, improve the serum Na+ level and quality of life of patients, and has good drug safety.

参考文献/References:

[1]栗小旭,杨静,任腾腾.沙库巴曲缬沙坦钠联合阿托伐他汀钙对糖尿病合并心力衰竭模型左心室重构通路的影响[J].中国心血管病研究,2025,23(1):58-63.[2]江丽华,席巍,蔡鑫.增殖型2型糖尿病视网膜病变患者外周血ADAMTS13表达及对阿托伐他汀干预效果的评估价值[J].河北医科大学学报,2024,45(9):1053-1057.[3]曹新营,邢彩耐,刘丽丽,等.钠-葡萄糖协同转运蛋白-2抑制剂治疗对高血压合并2型糖尿病患者血压及炎性因子水平影响[J].临床军医杂志,2024,52(9):955-957,961.[4]桑亚菲,袁静雅,赵倩,等.SGLT-2抑制剂对2型糖尿病肾病患者的心血管保护作用[J].心血管康复医学杂志,2024,33(4):449-455.[5]桑丽丽,朱丽丽,王海彦,等.不同剂量阿托伐他汀联合胰激肽原酶肠溶片治疗糖尿病动脉粥样硬化患者的疗效[J].川北医学院学报,2024,39(7):977-980.[6]梁岩,周彬,程艳玲.血脂康联合阿托伐他汀对老年糖尿病动脉粥样硬化合并高血压患者血脂水平影响[J].临床军医杂志,2024,52(3):291-293.[7]国家老年医学中心,中华医学会老年医学分会,中国老年保健协会糖尿病专业委员会.中国老年糖尿病诊疗指南(2024版)[J].协和医学杂志,2024,15(4):771-800.[8]李敏,高瑞超,张志佳,等.利拉鲁肽联合阿托伐他汀对肥胖2型糖尿病患者血糖和脂肪因子及肠道菌群的影响[J].中国医药,2024,19(1):55-59.[9]冷昌龙,周梅,李友维,等.阿托伐他汀预处理对高血糖诱导小鼠脑缺血后出血转化的影响[J].中华老年心脑血管病杂志,2024,26(1):92-96.[10]罗灵光,龙新平,韦少恒.阿托伐他汀抑制PI3K/AKT/FoxO1通路及高糖诱导的足细胞增殖、凋亡及氧化应激损伤[J].中国组织化学与细胞化学杂志,2023,32(6):562-569.[11]贺春晖,贺婷,杨进刚,等.匹伐他汀与阿托伐他汀对急性心肌梗死伴糖代谢异常患者血脂与血糖水平影响的对比研究[J].中国循环杂志,2023,38(9):930-936.[12]梁蒙,杨雀,陈伟国,等.达格列净联合阿托伐他汀治疗糖尿病心肌病疗效及对患者Klotho和心室重构的影响[J].陕西医学杂志,2023,52(7):898-901.[13]王佳美,钱美琪,王艳红.SGLT-2抑制剂对糖尿病合并射血分数保留心衰患者细胞外体积分数的影响[J].中华保健医学杂志,2023,25(2):142-146.[14]陈晓敏,张丽娜,李友佳.高龄老年2型糖尿病患者多重用药特点分析[J].中国全科医学,2023,26(10):1271-1277.[15]张菊云,蒙绪标,符兰芳,等.达格列净联合阿托伐他汀治疗糖尿病肾病的效果及对患者胰岛功能和机体微炎症状态的影响[J].中国医药,2024,19(1):60-64.[16]荆强,王兆军,刘萍.钠—葡萄糖协同转运蛋白2抑制剂对肥胖2型糖尿病患者糖脂代谢、氧化应激指标的影响[J].中国临床医生杂志,2022,50(12):1440-1443.[17]黄馨谅,邵亚婷,张盼,等.SGLT-2抑制剂辅助降糖治疗对老年2型糖尿病患者尿酸水平及血管内皮功能的影响[J].广西医学,2022,44(22):2591-2595.[18]易卓卓,李青.SGLT-2抑制剂对2型糖尿病患者血糖波动的影响[J].湖南师范大学学报(医学版),2022,19(5):52-55.[19]庞雅平,姜兰叶,李秀芬,等.2型糖尿病合并高血压患者应用SGLT-2抑制剂后对糖脂代谢及颈动脉重构的影响[J].标记免疫分析与临床,2022,29(9):1536-1541.[20]陈丽萍,张德芳,赵银.阿托伐他汀联合阿司匹林治疗糖尿病肾微血管病变的效果及对P-选择素、TNF-α、hs-CRP的影响[J].临床误诊误治,2022,35(8):35-38.[21]孙海燕,王云成,田晶.不同剂量阿托伐他汀对伴2型糖尿病急性脑梗死患者预后的影响[J].中国老年学杂志,2022,42(5):1065-1068.[22]王晓燕,万廷信,李银霞,等.阿托伐他汀联合达格列净治疗糖尿病肾病的疗效及安全性分析[J].药物评价研究,2022,45(2):337-342.

相似文献/References:

[1]张西园.糖尿病与结直肠癌患者预后相关研究进展[J].医学信息,2018,31(01):55.[doi:10.3969/j.issn.1006-1959.2018.01.020]
　ZHANG Xi-yuan.Research Progress in the Relationship between Diabetes and the Prognosis of Colorectal Cancer[J].Journal of Medical Information,2018,31(24):55.[doi:10.3969/j.issn.1006-1959.2018.01.020]
[2]耿金萍.综合护理对甲状腺良性肿瘤并糖尿病患者手术效果的影响分析[J].医学信息,2018,31(01):163.[doi:10.3969/j.issn.1006-1959.2018.01.064]
　GENG Jin-ping.Analysis of the Effect of Comprehensive Nursing on the Surgical Effect of Thyroid Benign Tumor and Diabetic Patients[J].Journal of Medical Information,2018,31(24):163.[doi:10.3969/j.issn.1006-1959.2018.01.064]
[3]李雯婷,谈世华,余江明,等.踝肱指数检测在住院糖尿病患者中的重复性研究[J].医学信息,2018,31(03):159.[doi:10.3969/j.issn.1006-1959.2018.03.058]
　LI Wen-ting,TAN Shi-hua,YU Jiang-ming,et al.Study on Reproducibility of Ankle-brachial Index in Inpatients with Diabetes Mellitus[J].Journal of Medical Information,2018,31(24):159.[doi:10.3969/j.issn.1006-1959.2018.03.058]
[4]刘 静.冠状动脉粥样硬化性心脏病合并糖尿病的血脂检验结果分析[J].医学信息,2018,31(04):154.[doi:10.3969/j.issn.1006-1959.2018.04.057]
　LIU Jing.Analysis of Blood Lipid Test Results in Coronary Atherosclerotic Heart Disease Complicated with Diabetes Mellitus[J].Journal of Medical Information,2018,31(24):154.[doi:10.3969/j.issn.1006-1959.2018.04.057]
[5]谢勇丽,苏晓清,张雅薇.糖尿病痛性周围神经病变患者情绪调查分析[J].医学信息,2018,31(05):14.[doi:10.3969/j.issn.1006-1959.2018.05.005]
　XIE Yong-li,SU Xiao-qing,ZHANG Ya-wei.Investigation and Analysis of Mood in Patients with Diabetic Peripheral Neuropathy[J].Journal of Medical Information,2018,31(24):14.[doi:10.3969/j.issn.1006-1959.2018.05.005]
[6]张雅薇,朱明慧.首发为动眼神经麻痹的糖尿病合并动眼神经麻痹误诊为痛性眼肌麻痹1例分析[J].医学信息,2018,31(05):23.[doi:10.3969/j.issn.1006-1959.2018.05.008]
　ZHANG Ya-wei,ZHU Ming-hui.An Analysis of a Case of Diabetes Mellitus with Oculomotor Nerve Palsy Misdiagnosed as Painful Ophthalmoplegia[J].Journal of Medical Information,2018,31(24):23.[doi:10.3969/j.issn.1006-1959.2018.05.008]
[7]张宇宁.黄酮类化合物治疗糖尿病及其并发症的研究[J].医学信息,2018,31(05):50.[doi:10.3969/j.issn.1006-1959.2018.05.018]
　ZHANG Yu-ning.Study on Flavonoids in the Treatment of Diabetes Mellitus and its Complications[J].Journal of Medical Information,2018,31(24):50.[doi:10.3969/j.issn.1006-1959.2018.05.018]
[8]柳 梅.头孢哌酮钠舒巴坦钠治疗糖尿病并发尿路感染的 临床效果观察[J].医学信息,2018,31(07):139.[doi:10.3969/j.issn.1006-1959.2018.07.047]
　LIU Mei.Clinical Efficacy of Cefoperazone Sodium and Sulbactam Sodium in Treatment of Diabetes Complicated with Urinary Tract Infection[J].Journal of Medical Information,2018,31(24):139.[doi:10.3969/j.issn.1006-1959.2018.07.047]
[9]吕桂英.影响糖尿病患者药物治疗依从性相关因素临床分析[J].医学信息,2018,31(08):109.[doi:10.3969/j.issn.1006-1959.2018.08.036]
　LV Gui-ying.Clinical Analysis of Factors Related to Compliance with Drug Therapy in Patients with Diabetes Mellitus[J].Journal of Medical Information,2018,31(24):109.[doi:10.3969/j.issn.1006-1959.2018.08.036]
[10]刘爱君.糖化血红蛋白测定在糖尿病诊断中的应用价值分析[J].医学信息,2018,31(08):161.[doi:10.3969/j.issn.1006-1959.2018.08.057]
　LIU Ai-jun.Analysis of the Value of Determination of Glycosylated Hemoglobin in the Diagnosis of Diabetes Mellitus[J].Journal of Medical Information,2018,31(24):161.[doi:10.3969/j.issn.1006-1959.2018.08.057]

更新日期/Last Update: 1900-01-01